Amino Acid Sequence Disclosed In Whole Or In Part; Or Conjugate, Complex, Or Fusion Protein Or Fusion Polypeptide Including The Same Patents (Class 424/185.1)
  • Patent number: 10675339
    Abstract: The present invention relates to methods for the recombinant expression of Chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes Chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter. The method of the invention allows expression of MOMP in the outer membrane of the cell, which leads to protein folding that is more like native MOMP relative to a MOMP protein that is expressed intracellularly. Also provided by the invention are uses of the recombinant MOMP in pharmaceutical compositions and methods for the treatment and/or prophylaxis of Chlamydia infection and/or the effects thereof.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: June 9, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Lan Zhang, Zhiyun Wen, Craig T. Przysiecki, Puneet Khandelwal
  • Patent number: 10648966
    Abstract: A conductive channel-containing membrane includes a membrane layer, and a SPP1 connector polypeptide variant that is incorporated into the membrane layer to form an aperture through which conductance can occur when an electrical potential is applied across the membrane. A method of sensing a molecule, such as a polypeptide or nucleic acid molecule, makes use of the conductive channel-containing membrane. A method of DNA sequence makes use of the conductive channel-containing membrane.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: May 12, 2020
    Assignee: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Peixuan Guo, Shaoying Wang
  • Patent number: 10626174
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 21, 2020
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Patent number: 10624934
    Abstract: Provided herein are compositions comprising a biocompatible microsphere, a biofilm-generating probiotic bacterium, a prebiotic, and/or a prebiofilmic. Methods for preparing and formulating the compositions and methods for treating or preventing a disease using the compositions are also provided.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: April 21, 2020
    Assignees: Research Institute at Nationwide Children's Hospital, Ohio State Innovation Foundation
    Inventors: Steven D. Goodman, Lauren O. Bakaletz, Michael Bailey, Gail Besner
  • Patent number: 10617748
    Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a tumor-associated antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the treatment of a tumor or in the treatment or prevention of a tumor relapse, and in the manufacture of medicaments therefore.
    Type: Grant
    Filed: January 5, 2015
    Date of Patent: April 14, 2020
    Assignees: LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 10610585
    Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: April 7, 2020
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Baylor Research Institute, Universite Paris Est Creteil Val De Marne, Assistance Publique Hopitaux de Paris
    Inventors: Yves Levy, Gerard Zurawski, Sandra Zurawski, Anne-Laure Flamar
  • Patent number: 10610574
    Abstract: Methods of treating an age-related disorder in a subject are provided. Aspects of the methods include administering to the subject a nucleic acid vector including a coding sequence for telomerase reverse transcriptase (TERT) and/or telomerase RNA (TR). Gene therapy methods are also provided. Aspects of the invention further include compositions, e.g., nucleic acid vectors and kits, etc., that find use in methods of the invention.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: April 7, 2020
    Assignee: Sierra Sciences, LLC
    Inventors: William H. Andrews, Lancer K. Brown, Hamid Mohammadpour, Laura A. Briggs
  • Patent number: 10611836
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 7, 2020
    Assignee: Genentech, Inc.
    Inventors: Jane Grogan, Robert J. Johnston, Bryan Irving, Jason Hackney, Xin Yu, Dan Eaton, Kristin Bowles, Laetitia Comps-Agrar
  • Patent number: 10604570
    Abstract: The present invention relates to a chimeric antigen-receptor (CAR) signalling system comprising; (i) a targeting component comprising an antigen-binding domain, a transmembrane domain and a first heterodimerization domain; and (ii) an intracellular signalling component comprising a signalling domain and a second heterodimerization domain; wherein spontaneous heterodimerization between the first and second heterodimerization domains causes the targeting component and signalling component to form a functional CAR complex.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: March 31, 2020
    Assignee: UCL BUSINESS LTD
    Inventors: Martin Pulé, Shaun Cordoba
  • Patent number: 10590169
    Abstract: Methods and compositions for inhibiting and/or interfering with interactions between (1) programmed Death-1 protein (also known as CD279) and (2) programmed death-ligand 1 (PD-L1) and/or programmed death-ligand 2 (PD-L2) are disclosed. In addition, methods and compositions for increasing IL-2 levels in a cell, and methods and compositions for preventing, treating, or ameliorating the effects of cancer in a subject, are disclosed.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: March 17, 2020
    Assignee: Virogin Biotech Canada Ltd
    Inventors: William Jia, Xuexian Bu, I-Fang Lee
  • Patent number: 10583199
    Abstract: Disclosed are biodegradable nanocarriers that have a net positive surface charge and zeta potential between about +2 to about +20 mV. The positive surface charge of the nanocarriers is provided by peptides that are covalently attached to the surface of the nanocarriers. The nanocarriers may comprise a drug and may be administered for localized and sustained delivery of the drug.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: March 10, 2020
    Assignee: Northwestern University
    Inventors: Jack Henkin, Ignacio Melgar-Asensio
  • Patent number: 10568926
    Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present disclosure relates to the use of des-aspartate-angiotensin I and/or its derivatives that are its metabolites for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions. Specifically, the disclosure relates to the treatment of a malignant growth, an invasive growth, a tumor, a tumor metastasis, a cancer or combinations thereof and to modulate the level or effect of HSP90 or other inflammation-linked molecules in relevant tissue or blood.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: February 25, 2020
    Assignee: SimPharma Pte Ltd
    Inventor: Meng Kwoon Sim
  • Patent number: 10570175
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: February 25, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Juliane Walz, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
  • Patent number: 10563224
    Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: February 18, 2020
    Assignee: Etubics Corporation
    Inventors: Frank R. Jones, Elizabeth Gabitzsch
  • Patent number: 10555990
    Abstract: The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: February 11, 2020
    Assignees: NOVARTIS AG, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Lori Jennings, Kristen Johnson, Peter Schultz
  • Patent number: 10556002
    Abstract: Bivalent immunogenic compositions against anthrax and plague are disclosed herein. One bivalent immunogenic composition comprises a triple fusion protein containing three antigens, F1 and V from Yersinia pestis and PA antigen from Bacillus anthracia fused in-frame and retaining structural and functional integrity of all three antigens. Another bivalent immunogenic composition comprises bacteriophage nanoparticles arrayed with these three antigens on the capsid surface of the bacteriophage nanoparticles. These bivalent immunogenic compositions are able to elicit robust immune response in a subject administered said the bivalent immunogenic compositions and provide protection to the subject against sequential or simultaneous challenge with both anthrax and plague pathogens.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: February 11, 2020
    Assignee: The Catholic University of America
    Inventor: Venigalla B. Rao
  • Patent number: 10548976
    Abstract: Provided herein are methods of treating beta-thalassemia in a subject comprising administering to the subject an activin type II receptor (ActRII) signaling inhibitor (e.g., an activin ligand trap) and utilizing one or more in vitro cell culture methods provided herein in (i) selection of the subject to be treated according to the methods provided herein; and/or (ii) monitoring of the subject being treated according to the methods provided herein.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: February 4, 2020
    Assignee: Celgene Corporation
    Inventors: Maria Cappellini, Victoria Sung
  • Patent number: 10537626
    Abstract: The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: January 21, 2020
    Assignee: Cytlimic Inc.
    Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
  • Patent number: 10537610
    Abstract: Methods for treating breast cancer, the methods can include administering to a subject an effective amount of a cell adhesion molecule Receptor (F11R peptide).
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: January 21, 2020
    Inventors: Anna Babinska, Radoslaw Bednarek, Elizabeth Kornecki, Moro O. Salifu, Yigal H. Ehrlich, Maria Swiatkowska, Cristina C. Clement
  • Patent number: 10526386
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: January 7, 2020
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Oliver Schoor, Andrea Mahr, Toni Weinschenk, Anita Wiebe, Jens Fritsche, Harpreet Singh
  • Patent number: 10512679
    Abstract: The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: December 24, 2019
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Oliver Schoor, Andrea Mahr
  • Patent number: 10500261
    Abstract: The invention relates to immunogenic synthetic constructs capable of inducing an immune response against Campylobacter jejuni (C. jejuni) in a subject comprising one or more monosaccharides comprising one or more MeOPN moieties. Specifically, the invention relates to immunogenic synthetic constructs capable of inducing an immune response against C. jejuni in a subject comprising one or more MeOPN-6-Gal monosaccharides, one or more MeOPN-4-Gal monosaccharides, and/or one or more MeOPN-2-Gal monosaccharides. The invention also relates to compositions comprising the immunogenic synthetic constructs, and methods of inducing an immune response against C. jejuni in a subject comprising administering the immunogenic synthetic constructs, and/or compositions comprising the immunogenic synthetic constructs, to the subject. Methods of treating, preventing, or ameliorating a C.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: December 10, 2019
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: Patricia Guerry, Mario Artur Monteiro, Yuening Jiao, Brittany Michele Pequegnat
  • Patent number: 10494408
    Abstract: Nucleotide sequences are disclosed that encode novel chimeric insecticidal proteins exhibiting Lepidopteran inhibitory activity. Particular embodiments provide compositions and transformed plants, plant parts, and seeds containing the recombinant nucleic acid molecules encoding one or more of the chimeric insecticidal proteins.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: December 3, 2019
    Assignee: Monsanto Technology LLC
    Inventors: James A. Baum, Thomas A. Cerruti, Crystal L. Dart, Leigh H. English, Stanislaw Flasinski, Xiaoran Fu, Victor M. Guzov, Arlene R. Howe, Jay P. Morgenstern, James K. Roberts, Sara A. Salvador, Jinling Wang
  • Patent number: 10487143
    Abstract: The invention generally relates to compositions and methods for preventing and treating cancer. More specifically, the invention relates to antigenic polypeptides and their use in cancer vaccines that may be used, in part, to treat cancer types dependent upon HER2-mediated signaling.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: November 26, 2019
    Assignee: Duke University
    Inventors: Herbert K. Lyerly, Takuya Osada, Zachary C. Hartman
  • Patent number: 10478471
    Abstract: A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a MHC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: November 19, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10464977
    Abstract: Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: November 5, 2019
    Assignees: University of Maryland, Baltimore, University of Maryland, College Park
    Inventors: Mary Ann Jabra-Rizk, Amy J. Karlsson, Svetlana Pavlova Ikonomova
  • Patent number: 10463747
    Abstract: The invention describes the development of more potent peptide vaccines to prevent or treat infections or cancer and their administration to a subject in order to elicit a T cell response in the subject. Small synthetic peptides from the known sequences of viral, bacterial, parasitic or tumor antigens are modified so they can spontaneously form complexes with a synthetic nucleic acid, such as Poly IC, that functions as an immunological adjuvant. The peptide-nucleic acid complexes are dramatically more immunogenic as compared to the separate components. The procedure for developing the vaccine involves the conjugation of a synthetic peptide containing a C residue to poly-K using a bi-functional cross-linking reagent (SMCC). The peptide/poly-K complex was then formulated with CMC and poly-IC to produce a self-adjuvant vaccine that was 36-fold more effective as compared to the same peptide administered mixed with the same adjuvant (but not complexed to it).
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: November 5, 2019
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventor: Esteban Celis
  • Patent number: 10449250
    Abstract: Provided is a humanized antibody and chimeric antibody that specifically binds human sclerostin. The antibodies can be used for treating human bone metabolism related diseases such as osteoporosis (OP).
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: October 22, 2019
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jiajian Liu, Yayuan Fu, Haoying Zhang, Yifang Wang, Zhen Zhang, Ling Zhang, Dongbing Cui, Lianshan Zhang, Weikang Tao
  • Patent number: 10441649
    Abstract: A variety of targeting moiety peptide epitope complexes (TPECs) are described in different embodiments. In each of the embodiments, however, a targeting moiety may be used to deliver the TPEC to an area of unwanted cells, allowing for a therapeutic effect to be delivered locally. The TPEC also contains a plurality of T-cell epitopes. The TPEC further comprises cleavage sites that release the T-cell epitopes from the targeting agent, and in some embodiments from each other, when they are in the microenvironment of the unwanted cells. Although the arrangement and number of T-cell epitopes varies in different embodiments described herein, once cleaved from the targeting agent (and any neighboring T-cell epitopes), the T-cell epitopes function by stimulating an immune response against the unwanted cells.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: October 15, 2019
    Assignee: The University of Birmingham
    Inventors: Mark Cobbold, David Millar
  • Patent number: 10435449
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: October 8, 2019
    Assignee: INMATICS BIOTECHNOLOGIES GMBH
    Inventors: Colette Song, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Patent number: 10420801
    Abstract: A method for suppressing an immune response is provided. The method involves administration of isolated lymphoid tissue-derived suppressive stromal cells (LSSC) to a subject in need of such treatment in an amount effective to suppress the immune response in the subject. The invention also involves a method to isolate LSSC by digesting lymphoid tissue fragments using a combination of an enzyme mix and agitation and then collecting the LSSC. Pharmaceutical preparations comprising LSSC are also provided.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 24, 2019
    Assignees: The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Anne Fletcher, Shannon J. Turley, Biju Parekkadan
  • Patent number: 10420816
    Abstract: A method of treating a patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has gastric cancer, gastrointestinal cancer, colorectal cancer, pancreatic cancer, lung cancer, and/or renal cancer. A method of treating a patient who has cancer includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the cancer.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: September 24, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
  • Patent number: 10407697
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: September 10, 2019
    Assignees: The Regents of the University of California, University of Vienna
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10398905
    Abstract: The present invention relates to methods for delivering at least one agent unto or into a biological sample or a biological subject. The methods comprise a step of contacting the biological sample or subject with a payload-carrying nanostructure. The nanostructure can be a porous low density nanostructure.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: September 3, 2019
    Assignee: NVIGEN, INC.
    Inventor: Aihua Fu
  • Patent number: 10385360
    Abstract: The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: August 20, 2019
    Assignees: The Regents of the University of California, University of Vienna, Emmanuelle Charpentier
    Inventors: Jennifer A. Doudna, Martin Jinek, Krzysztof Chylinski, Emmanuelle Charpentier
  • Patent number: 10383928
    Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: August 20, 2019
    Assignee: ULTIMOVACS AS
    Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
  • Patent number: 10376571
    Abstract: Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD154 polypeptide or an HMGB1 polypeptide.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 13, 2019
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, THE TEXAS A&M UNIVERSITY SYSTEM
    Inventors: Lisa Bielke, Sherryll Layton, Billy Hargis, Neil R. Pumford, Olivia B. Faulkner, Luc Berghman, Daad Abi-Ghanem
  • Patent number: 10363282
    Abstract: Materials and methods for treating an infection or disease, activating an immune cell at a site of infection or disease, and for directly killing microorganisms, using response-selective carboxy-terminal C5a analogs, are provided.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: July 30, 2019
    Assignees: Board of Regents of The University of Nebraska, San Diego State University Research Foundation
    Inventors: Sam D. Sanderson, Joy Arlene Phillips, Edward Leroy Morgan, Marilyn Louise Thoman, Tamsin Sheen, Kelly S. Doran, Elizabeth Louise Virts, Tammy Kielian, Mark Hanke
  • Patent number: 10363293
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 30, 2019
    Assignee: Turnstone Limited Partnership
    Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
  • Patent number: 10363294
    Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: July 30, 2019
    Assignees: GlobeImmune, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Claudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
  • Patent number: 10357554
    Abstract: Disclosed are AMA-1 immunogenic peptides and epitopes, nucleotide sequences encoding the peptides and epitopes, compositions, and vaccines including the peptides and/or epitopes. Antibodies that specifically bind to AMA-1 and the AMA-1 epitopes and immunogenic peptides disclosed herein are also provided. The disclosure provides for expression vectors, host cells, and methods for making the polypeptides and antibodies. Also provided are methods of treatment, prevention, vaccination, and/or immunization of a subject against malaria and the clinical indications associated with malaria.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: July 23, 2019
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY
    Inventors: Sheetij Dutta, Adrian Batchelor, Michael Foley
  • Patent number: 10357589
    Abstract: Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: July 23, 2019
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Yair Pilpel, Ashley Deanglis, Yuri Zherdev, Sivan Doron, Israel Nur
  • Patent number: 10349640
    Abstract: The present invention provides a prophylactic or therapeutic agent for a kidney disease, comprising Apoptosis Inhibitor of Macrophage (AIM) or a partial peptide thereof, or a nucleic acid comprising a base sequence encoding the same, or a screening method for a prophylactic or therapeutic agent for a kidney disease, comprising using an animal obtained by subjecting a non-human mammal deficient in AIM expression to unilateral ureteral obstruction or transient kidney ischemia/reperfusion and the like.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: July 16, 2019
    Inventor: Toru Miyazaki
  • Patent number: 10350291
    Abstract: The present invention relates to antigen-specific immune regulatory response. Methods for detecting an antigen-specific immune regulatory response, methods for selecting candidate vaccine recipients, and methods for improved vaccination strategies are presented.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: July 16, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Douglas G. McNeel, William J. Burlingham
  • Patent number: 10342859
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: July 9, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10335471
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: July 2, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 10329326
    Abstract: The subject invention pertains to a modified MC1R peptide ligand comprising a peptide that is a melanocortin 1 receptor (MC1R) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MC1R peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MC1R-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MC1R. The subject invention also pertains to a MC1R peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MC1R or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: June 25, 2019
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM, H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., INTEZYNE TECHNOLOGIES INC.
    Inventors: Robert J. Gillies, David L. Morse, Natalie M. Barkey, Kevin N. Sill, Josef Vagner, Narges K. Tafreshi, Jonathan L. Sessler, Christian Preihs, Victor J. Hruby
  • Patent number: 10316075
    Abstract: Recombinant polypeptides comprising a DR?1 domain, an antigenic peptide, and a linker sequence are disclosed. The linker sequence comprises a first glycine-serine spacer, a thrombin cleavage site and a second glycine-serine spacer. Further disclosed are pharmaceutical compositions comprising the recombinant polypeptides, methods of treating inflammatory disease using said pharmaceutical compositions, and expression constructs comprising nucleic acids that encode the recombinant polypeptides.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: June 11, 2019
    Assignees: Oregon Health & Science University, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Arthur A. Vandenbark, Roberto Meza-Romero, Gil Benedek, Gregory G. Burrows
  • Patent number: 10317402
    Abstract: A method for identifying T-cell epitopes which can be used to elicit T cells targeting cells capable of regenerating cancers is disclosed. The method identifies T-cell epitopes with a high curative potential, high potency and high probability of T cell recognition (HP). The method includes: (i) identifying high curative potential tumor protein target i.e., identifying HP-TP; (ii) identifying peptide sequences within the protein sequence of an HP-TP that have a high probability of eliciting T cell killing; and (iii) qualifying the sequence specificity based on the fold difference between the specific target and non-targets. The identified T-cell epitopes include a core sequence of 9 amino acids homologous to a sequence expressed within a qualified HP-TP. The T-cell epitopes can be used in a method for reprogramming T cells to selectively attack tumor cells capable of perpetuating a tumor and treating patients, for example, cancer patients.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: June 11, 2019
    Assignee: Verik Bio, Inc.
    Inventors: Nancy Parenteau, Joseph Laning, Janet Young
  • Patent number: RE48023
    Abstract: A method for treating a vascular-related disease in a subject in need thereof, includes administering to the subject a peptide having a sequence Xaa-Gly-Asp. The peptide may have a sequence of SEQ ID NOS: 1, 2, 4, 6 to 10. The vascular-related disease may be edema and/or ischemia caused by blood leakage of blood vessel walls, damages of blood vessels or abnormal angiogenesis.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: June 2, 2020
    Assignee: EYEGENE INC.
    Inventors: Doo-Sik Kim, Yang-Je Cho, Won-Il Yoo, Oh-Woong Kwon, Jin-Wook Jang, Hyeong-Joon Lim, Soo-Mee Kwon